Mesothelioma Research Today is a free monthly online journal that collates and summarizes the latest research about Mesothelioma, including details on asbestos, symptoms, treatment, causes.

Volume 1 (2005), Issue 3 (May)

1. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
   J Thorac Cardiovasc Surg, 129(5): 1010-7. [Abstract] [Full-text]
2. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma.
   Clin Cancer Res, 11(9): 3303-8. [Abstract] [Full-text]
3. Pemetrexed-cisplatin combination in mesothelioma.
   Expert Rev Anticancer Ther, 5(2): 231-7. [Abstract] [Full-text]
4. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.
   Am J Respir Crit Care Med, 171(10): 1168-77. [Abstract] [Full-text]
5. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma.
   Hum Pathol, 36(4): 372-80. [Abstract] [Full-text]
6. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
   Lung Cancer, 48(3): 429-34. [Abstract] [Full-text]
7. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
   Lung Cancer, 48(3): 423-8. [Abstract] [Full-text]
8. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.
   Clin Cancer Res, 11(10): 3814-20. [Abstract] [Full-text]
9. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase.
   Mol Cancer Ther, 4(5): 835-42. [Abstract] [Full-text]
10. Solitary fibrous tumour of the epididymis: MRI features.
    Br J Radiol, 78(930): 565-8. [Abstract] [Full-text]
11. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
    J Clin Oncol, 23(15): 3495-501. [Abstract] [Full-text]
12. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
    Ann Oncol, 16(6): 923-7. [Abstract] [Full-text]
13. Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells.
    Cancer, 103(11): 2427-33. [Abstract] [Full-text]
14. Giant solitary fibrous tumor of the pleura.
    Thorac Cardiovasc Surg, 53(3): 185-8. [Abstract] [Full-text]

© 2005-2008 Mesothelioma Research Today. All Rights Reserved.